Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103642849A details a high-yield Geotrichum candidum reduction method for chiral intermediates, offering significant cost and supply chain advantages.
Patent CN1228448C details a yeast-catalyzed route for (R)-2-halo-1-(substituted phenyl) ethanol, offering significant cost reduction in API manufacturing and superior stereocontrol.
Patent CN105368828A enables high-yield UDCA synthesis via recombinant E. coli ensuring supply chain stability and cost efficiency for pharmaceutical intermediates manufacturing globally.
Patent CN112852768B reveals engineered carbonyl reductase mutants for high-purity chiral nitrile synthesis, offering significant cost reduction in API manufacturing and scalable green chemistry solutions.
Novel aminotransferase patent enables high-purity sitagliptin intermediate production with reduced costs and enhanced supply chain reliability for global pharmaceutical manufacturers.
Patent CN120718880A reveals high-efficiency biocatalysis for chiral amines. Achieve superior purity and reduced manufacturing costs with scalable enzyme technology.
Patent CN116875575A reveals mutant enzyme for L-glufosinate. Achieves 99% conversion in 4h. Offers cost reduction and supply chain reliability for agrochemical manufacturing.
Patent CN102382780B reveals a novel Microbacterium oxydans strain for high-purity chiral alcohol production, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN102482648B details stereoselective reduction enhancing supply chain reliability and purity for pharmaceutical manufacturing.
Patent CN114107236B reveals a high-efficiency ketoreductase mutant for synthesizing Ibrutinib intermediates, offering superior yield and scalability for pharmaceutical manufacturing.
Patent CN116334022B reveals high-efficiency transaminase mutant for Rivastigmine intermediate. Offers superior yield and purity for scalable pharmaceutical manufacturing.
Patent CN113789310B reveals high-yield transaminase route for moxifloxacin intermediates, eliminating DMSO for cost-effective and scalable API manufacturing.
Patent CN111321178B reveals a high-yield enzymatic route for L-2-aminobutanamide. Discover cost-effective manufacturing and supply chain advantages for API intermediates.
Patent CN112662709A reveals a dual-enzyme method for (R)-citronellol. Achieve >99% e.e. value and green manufacturing for reliable fragrance supply chains.
Patent CN1240844C details a novel microbial hydroxylation process for statin intermediates using non-sporulating bacteria, offering superior scalability and purity for API manufacturing.
Novel ketoreductase mutant enables high-purity pharmaceutical intermediates manufacturing with substantial cost reduction and enhanced supply chain reliability for global partners.
Patent CN109402074B reveals high-activity monooxygenase mutants for chiral sulfoxide production. Discover cost reduction in pharmaceutical intermediate manufacturing and reliable supply chain solutions.
Patent CN115975968B reveals novel amine dehydrogenase mutants for high-purity chiral amines. Offers significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN104342463B reveals high-purity biocatalytic route. Enhances supply chain reliability and reduces manufacturing costs for gabapentin intermediates significantly for global buyers.
Patent CN112852769A reveals a high-yield enzymatic route for (S)-1-(2-methoxy-3-bromophenyl) ethanol. Discover cost-effective, green manufacturing solutions for this critical API intermediate.